Search research articles
Contact Us
Filters
Showing results (191-200 of 197) with videos related to
Page
of 20
Sort By:
You have reached the last page of results.
This site can display upto 197 results.
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
Journal of Medical Genetics
|
March 4, 2008
Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
L Faivre, G Collod-Beroud, A Child, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2009
Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion
L Faivre, G Collod-Beroud, B Callewaert, et al.
European Journal of Human Genetics : EJHG
|
November 13, 2008
Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation
L Faivre, G Collod-Beroud, B Callewaert, et al.
Clinical Genetics
|
May 14, 2011
The new Ghent criteria for Marfan syndrome: what do they change?
L Faivre, G Collod-Beroud, L Adès, et al.
American Journal of Human Genetics
|
August 19, 2007
Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study
L Faivre, G Collod-Beroud, B L Loeys, et al.
Page
of 20
Search research articles
Search
Showing results (191-200 of 197) with videos related to
Sort By:
Page
of 20
You have reached the last page of results.
This site can display upto 197 results.
ESMO Open
|
April 2, 2025
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study
C Marchetti, A Fagotti, R Fruscio, et al.
ESMO Open
|
May 30, 2025
Response to letter re: Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study: Not all BRCA mutations are equal: functional context and mutation type as co-determinants of PARP inhibitor response
C Marchetti, A Fagotti, R Fruscio, et al.
Journal of Medical Genetics
|
March 4, 2008
Contribution of molecular analyses in diagnosing Marfan syndrome and type I fibrillinopathies: an international study of 1009 probands
L Faivre, G Collod-Beroud, A Child, et al.
American Journal of Medical Genetics. Part A
|
April 9, 2009
Pathogenic FBN1 mutations in 146 adults not meeting clinical diagnostic criteria for Marfan syndrome: further delineation of type 1 fibrillinopathies and focus on patients with an isolated major criterion
L Faivre, G Collod-Beroud, B Callewaert, et al.
European Journal of Human Genetics : EJHG
|
November 13, 2008
Clinical and mutation-type analysis from an international series of 198 probands with a pathogenic FBN1 exons 24-32 mutation
L Faivre, G Collod-Beroud, B Callewaert, et al.
Clinical Genetics
|
May 14, 2011
The new Ghent criteria for Marfan syndrome: what do they change?
L Faivre, G Collod-Beroud, L Adès, et al.
American Journal of Human Genetics
|
August 19, 2007
Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study
L Faivre, G Collod-Beroud, B L Loeys, et al.
Page
of 20